Core One Labs Inc. (CLABF)
USD 0.04
(-10.28%)
USD 0.04
(-10.28%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 8.25 Million CAD | -34.71% |
| 2021 | 12.64 Million CAD | 77.16% |
| 2020 | 7.13 Million CAD | -51.35% |
| 2019 | 14.66 Million CAD | 43.31% |
| 2018 | 10.23 Million CAD | -22.23% |
| 2017 | 13.16 Million CAD | 559.18% |
| 2016 | 1.99 Million CAD | 79.86% |
| 2015 | 1.11 Million CAD | 158.07% |
| 2014 | 430.16 Thousand CAD | 31.05% |
| 2013 | 328.25 Thousand CAD | -28.54% |
| 2012 | 459.33 Thousand CAD | 76.49% |
| 2011 | 260.26 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 2.98 Million CAD | 21.63% |
| 2023 Q2 | 467.77 Thousand CAD | -84.34% |
| 2023 Q3 | 901.63 Thousand CAD | 92.75% |
| 2022 FY | 8.25 Million CAD | -34.71% |
| 2022 Q4 | 2.45 Million CAD | 111.5% |
| 2022 Q1 | 3.32 Million CAD | 273.39% |
| 2022 Q2 | 1.67 Million CAD | -49.66% |
| 2022 Q3 | 1.16 Million CAD | -30.59% |
| 2021 FY | 12.64 Million CAD | 77.16% |
| 2021 Q1 | 7.96 Million CAD | 403.72% |
| 2021 Q2 | 2.18 Million CAD | -72.63% |
| 2021 Q3 | 1.52 Million CAD | -29.95% |
| 2021 Q4 | 889.97 Thousand CAD | -41.75% |
| 2020 Q2 | 1 Million CAD | -6.72% |
| 2020 Q3 | 3.65 Million CAD | 265.04% |
| 2020 Q4 | 1.58 Million CAD | -56.74% |
| 2020 FY | 7.13 Million CAD | -51.35% |
| 2020 Q1 | 1.07 Million CAD | -83.32% |
| 2019 Q2 | 3.33 Million CAD | 40.8% |
| 2019 FY | 14.66 Million CAD | 43.31% |
| 2019 Q4 | 6.43 Million CAD | 154.35% |
| 2019 Q1 | 2.36 Million CAD | 120.4% |
| 2019 Q3 | 2.53 Million CAD | -24.12% |
| 2018 Q4 | 1.07 Million CAD | -72.22% |
| 2018 FY | 10.23 Million CAD | -22.23% |
| 2018 Q2 | 3.16 Million CAD | 49.22% |
| 2018 Q1 | 2.12 Million CAD | -68.99% |
| 2018 Q3 | 3.86 Million CAD | 22.06% |
| 2017 Q2 | 959.16 Thousand CAD | 26.42% |
| 2017 Q1 | 758.68 Thousand CAD | 29.9% |
| 2017 Q4 | 6.84 Million CAD | 70.93% |
| 2017 FY | 13.16 Million CAD | 559.18% |
| 2017 Q3 | 4 Million CAD | 317.7% |
| 2016 Q2 | 373.61 Thousand CAD | 6.75% |
| 2016 Q3 | 688.98 Thousand CAD | 84.41% |
| 2016 Q4 | 584.03 Thousand CAD | -15.23% |
| 2016 FY | 1.99 Million CAD | 79.86% |
| 2016 Q1 | 350 Thousand CAD | 50.64% |
| 2015 Q2 | 375.38 Thousand CAD | 203.96% |
| 2015 Q4 | 232.34 Thousand CAD | -38.68% |
| 2015 Q3 | 378.9 Thousand CAD | 0.94% |
| 2015 FY | 1.11 Million CAD | 158.07% |
| 2015 Q1 | 123.49 Thousand CAD | -47.23% |
| 2014 Q3 | 102.6 Thousand CAD | 179.62% |
| 2014 Q1 | 56.87 Thousand CAD | -52.98% |
| 2014 Q2 | 36.69 Thousand CAD | -35.48% |
| 2014 FY | 430.16 Thousand CAD | 31.05% |
| 2014 Q4 | 234 Thousand CAD | 128.07% |
| 2013 Q2 | 49.66 Thousand CAD | -32.52% |
| 2013 FY | 328.25 Thousand CAD | -28.54% |
| 2013 Q1 | 73.59 Thousand CAD | -1.29% |
| 2013 Q3 | 84.05 Thousand CAD | 69.24% |
| 2013 Q4 | 120.94 Thousand CAD | 43.89% |
| 2012 Q3 | 74.29 Thousand CAD | -13.01% |
| 2012 Q1 | 225.07 Thousand CAD | 1543.14% |
| 2012 FY | 459.33 Thousand CAD | 76.49% |
| 2012 Q2 | 85.4 Thousand CAD | -62.06% |
| 2012 Q4 | 74.56 Thousand CAD | 0.36% |
| 2011 FY | 260.26 Thousand CAD | 0.0% |
| 2011 Q1 | 35.87 Thousand CAD | 0.0% |
| 2011 Q2 | 42.36 Thousand CAD | 18.11% |
| 2011 Q3 | 168.33 Thousand CAD | 297.32% |
| 2011 Q4 | 13.69 Thousand CAD | -91.86% |
| 2010 Q3 | 14.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | -126.085% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -515.24% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -214.125% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 72.071% |
| GB Sciences, Inc. | 1.42 Million USD | -481.039% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -142.401% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -3650.359% |
| Skye Bioscience, Inc. | 13.54 Million USD | 39.076% |
| Zenith Capital Corp. | 8.94 Million USD | 7.708% |
| Agentix Corp. | 1.37 Million USD | -501.69% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -63.698% |
| Biomind Labs Inc. | 994.18 Thousand USD | -730.202% |
| ContraFect Corporation | 56.88 Million USD | 85.492% |
| CSL Limited | 3.44 Billion USD | 99.761% |
| CytoDyn Inc. | 18.05 Million USD | 54.293% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -342.708% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2018.695% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 85.631% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -1886.554% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -449.552% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -793.733% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 77.846% |
| SQZ Biotechnologies Company | 85.61 Million USD | 90.36% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -302.875% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 90.489% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -183.026% |
| Mesoblast Limited | 5.9 Million USD | -39.846% |
| Marizyme, Inc. | 19.23 Million USD | 57.101% |
| Genus plc | 147.7 Million USD | 94.412% |
| Pharming Group N.V. | 225.49 Million USD | 96.34% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 1.023% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -458.154% |
| IMV Inc. | 37.7 Million USD | 78.112% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -195.794% |
| MultiCell Technologies, Inc. | 567.42 USD | -1454504.35% |
| ONE Bio Corp. | 6.44 Million USD | -28.086% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 90.397% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 66.604% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -369.047% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -22.859% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 33114.864% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 48.447% |
| Alpha Cognition Inc. | 9.7 Million USD | 14.959% |
| Enzolytics Inc. | 2.17 Million USD | -278.696% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.462% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -690.586% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -243.199% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -67.83% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3053.571% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -236.157% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -4712.41% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -329.678% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 5.986% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -87.215% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -120.309% |
| Helix BioMedix, Inc. | 1.97 Million USD | -318.538% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1451.561% |
| Q BioMed Inc. | 3.43 Million USD | -140.169% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 24.048% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 91.691% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 64.075% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -349.771% |
| HST Global, Inc. | 140.9 Thousand USD | -5757.563% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -518.056% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -633.722% |
| Halberd Corporation | 74.84 Thousand USD | -10928.187% |
| Resverlogix Corp. | 12.71 Million USD | 35.071% |
| Cell Source, Inc. | 4.32 Million USD | -90.822% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -422.6% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -12.906% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -47277.969% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -234.597% |
| Kadimastem Ltd | 2.41 Million USD | -242.462% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -94.736% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -4447.878% |
| LadRx Corporation | 3.81 Million USD | -116.531% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -793.733% |
| Affymax, Inc. | 39.38 Million USD | 79.044% |
| Itoco Inc. | 919.14 Thousand USD | -797.98% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -637.597% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1388.374% |
| International Stem Cell Corporation | 5.27 Million USD | -56.587% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -116.058% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -32693.182% |
| Qrons Inc. | 643.67 Thousand USD | -1182.276% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -481.333% |
| SYBLEU INC | 160.87 Thousand USD | -5030.483% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -270.142% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1143.03% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -354.42% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -15578.956% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -40472.757% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 77.241% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -410.118% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1021.68% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -165.307% |
| Neutra Corp. | 243.82 Thousand USD | -3285.154% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 52.72% |
| PureTech Health plc | 144.59 Million USD | 94.292% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 59.718% |
| IXICO plc | 4.7 Million USD | -75.35% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 6.176% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 92.99% |
| CSL Limited | 3.89 Billion USD | 99.788% |
| Cellectis S.A. | 97.32 Million USD | 91.519% |